Hemagen Obtains Clearance to Market Three Assays to Diagnose Respitory Tract Disease.WALTHAM, Mass.--(BW HealthWire)--Dec. 2, 1997--Hemagen Diagnostics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :HMGN HMGN Hemagen Diagnostics, Inc. (stock symbol) , HMGNW; BSE See Bombay Stock Exchange. BSE See Boston Stock Exchange (BSE). :HGN) today announced it has obtained Food and Drug Administration clearance to market three new products - VIRGO(R) ANCA ANCA Armenian National Committee of America ANCA Anti-Neutrophil Cytoplasmic Antibody (medical) ANCA Australian National Choral Association ANCA Australian Nature Conservation Agency ANCA Airport Noise and Capacity Act Screen, VIRGO(R) cANCA, and VIRGO(R) pANCA - used to aid in the diagnosis of patients with Wegener's disease, a systemic vasculitis characterized by lesions in the upper and lower respitory tract and kidney. Dr. Carl Franzblau, president of Hemagen, stated that ANCA (anti-neutrophil cytoplasmic anitibodies) is found in nearly all patients with generalized Wegener's granulomatosis as well as in pantinued. "We believe our presence in the autoimmune market will be significantly enhanced with the additi medical diagnostic test kits used to aid in txcept for any historical information contained hmission reports and filings. CONTACT: Hemagen Diagnostics Inc. William Franzblau 781/890-3766 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion